MDAnderson Cancer Center
Welcome,         Profile    Billing    Logout  
 23 Trials 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Slingluff, Craig L
MEL60, NCT02126579: Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Completed
1/2
50
US
Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod, IFA
Craig L Slingluff, Jr, University of Virginia
Melanoma, Metastatic Melanoma, Mucosal Melanoma
11/19
05/21
Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed
1/2
33
US
6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma
01/24
01/24
Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Active, not recruiting
1/2
22
US
6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma, Ocular Melanoma, Uveal Melanoma
09/24
05/25
AM-003, NCT04116320: Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Active, not recruiting
1
5
US
Echopulse, Focused Ultrasound Ablation, FUSA, Poly ICLC, Hiltonol, Standard of Care PD-1 Therapy
Craig L Slingluff, Jr, Theraclion
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
02/24
02/24
Mel61, NCT02382549: A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Terminated
1
8
US
BRAF inhibitor, 6MHP, 6 melanoma helper peptide vaccine, MEK inhibitor
Craig L Slingluff, Jr, National Cancer Institute (NCI)
Melanoma
02/22
02/22
EXCILYNT, NCT05839912: Excision of Lymph Node Trial () (Mel69)

Recruiting
N/A
66
US
Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Craig L Slingluff, Jr
Melanoma
09/28
09/28
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Active, not recruiting
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
8
US
Asciminib, ABL001, Ascimininb + Nilotinib, ABL001 + TASIGNA, Asciminib + Imatinib, ABL001 + Gleevec, Asciminib + Dasatinib, ABL001 + Sprycel
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/25
02/27
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Recruiting
2
182
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
02/26
02/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Active, not recruiting
1
62
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
07/21
07/21
P-TRP-2447-14, NCT02530034: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Active, not recruiting
1
72
US
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
01/26
01/26
Cinciripini, Paul
NCT02162849: Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Active, not recruiting
4
204
US
Varenicline, Chantix, Nicotine Patch, Placebo Patch, Placebo Tablet, Sugar pill, Questionnaires, Surveys, Counseling Sessions, Lab Session, Saliva Test
M.D. Anderson Cancer Center, NAL PHARMA, Pfizer
Tobacco Use Cessation
06/25
06/25
NCT02271919: Varenicline and Combined NRT for Smoking Cessation

Active, not recruiting
4
631
US
Nicotine Lozenge, Commit, Nicotine Patch, NicoDerm CQ, Nicotine Skin Patch, Nicotine Transdermal Patch, Placebo, placebo therapy, PLCB, sham therapy, Tobacco Cessation Counseling, Varenicline, Champix, Chantix, CP-526555
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cigarette Smoker, Tobacco Use Disorder
06/25
06/25
NCT04604509: Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Recruiting
4
2010
US
Bupropion Hydrochloride Controlled-release, Bupropion HCl Controlled-release, Bupropion HCl Extended Release, Bupropion Hydrochloride Extended-Release, Forfivo XL, Wellbutrin SR, Wellbutrin XL, Zyban, Nicotine Replacement, Nicotine Replacement Therapy, NRT, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline, Champix, Chantix, CP-526555
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cigarette Smoking-Related Carcinoma
12/28
12/28
NCT01182766: New Treatment for Alcohol and Nicotine Dependence

Active, not recruiting
2/3
294
US
Topiramate with brief behavioral enhancement therapy, Topamax, Placebo with brief behavioral enhancement therapy, sugar pill
University of Virginia, National Institute on Alcohol Abuse and Alcoholism (NIAAA), M.D. Anderson Cancer Center, University of California, San Diego
Alcohol Dependence, Nicotine Dependence
06/22
06/22
NCT03059940: Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Active, not recruiting
1
630
US
Questionnaires, Surveys, Low Dose Computed Tomography Scan, LDCT, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, TTP, Carbon Monoxide (CO) Level Test, CO
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Pfizer
Smoking Cessation
06/24
06/24
NCT02282969: PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing

Recruiting
N/A
620
US
Interviews, Questionnaires, Surveys
M.D. Anderson Cancer Center, Patient-Centered Outcomes Research Institute
Health Knowledge, Attitudes, Practice
08/25
08/25
NCT03668769: Quitting Schedule Mobile Smartphone Application in Helping Participants to Quit Smoking

Withdrawn
N/A
19
NA
Internet Mobile Technology, www-mobile, Interview, Questionnaire Administration, Smoking Cessation Intervention, Smoking and Tobacco Use Cessation Interventions
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cigarette Smoker, Current Every Day Smoker, Current Smoker, Malignant Neoplasm
03/20
03/20
NCI-2019-02501, NCT02964182: Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers

Active, not recruiting
N/A
380
US
Cigarette, Nicotine Replacement, Nicotine Replacement Therapy, NRT, Questionnaire Administration, Survey Administration, Very Low Nicotine Content Cigarette, VLNCC, ECIG-Hi, ECIG-Lo
M.D. Anderson Cancer Center, National Institute on Drug Abuse (NIDA)
Cigarette Smoking-Related Carcinoma, Tobacco-Related Carcinoma
06/25
06/25
Patel, Sapna P
SWOG S1404, NCT02506153: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Active, not recruiting
3
1345
Europe, Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
09/23
01/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
380
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics U.S., Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
09/23
12/26
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT01585194: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Completed
2
67
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
12/19
05/24
SWOG S1801, NCT03698019: A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Checkmark Presentation of data from SWOG S181 trial for melanoma at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from SWOG S181 trial for melanoma at ESMO 2022
Active, not recruiting
2
313
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
09/22
09/24
NCT04633902: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Olaparib, Lynparza, Pembrolizumab, Keytruda
California Pacific Medical Center Research Institute, M.D. Anderson Cancer Center
Metastatic Melanoma
06/23
12/24
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Nasopharyngeal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/24
12/24
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab, Keytruda, pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT03068624: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ SLC45A2-specific T Lymphocytes, Autologous SLC45A2-specific CTLs, Autologous SLC45A2-specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
12/22
07/25
Syntrix-SX682-Melanoma-101, NCT03161431: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Checkmark Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Oct 2020 - Oct 2020: Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Recruiting
1
77
US
SX-682, Pembrolizumab, KEYTRUDA
Syntrix Biosystems, Inc., Massachusetts General Hospital, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Mayo Clinic, University of Rochester, M.D. Anderson Cancer Center, University of Miami
Melanoma Stage III, Melanoma Stage IV
06/25
06/26
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/24
09/24
TS-PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting
N/A
700
Europe, Canada, US, RoW
Columbia University
Uveal Melanoma
07/26
07/26
Balmes, Gener
No trials found

Download Options